Several trials that compared the efficacy and safety of EGFR TKIs from the first, second or third generation combined with anti-angiogenic therapy, such as small-molecule inhibitors of VEGFR-2 (vandetanib, nintedanib, axitinib, and cediranib) or anti-VEGF/VEGFR monoclonal antibodies (ramucirumab, which is specific for the VEGFR-2 extracellular domain, or bevacizumab, a VEGF-A inhibitor), have been conducted to evaluate the efficacy of combination therapy in mutated NSCLC (Figure 1). This evidence concerns the gene EGFR and non-small cell lung carcinoma.